Mazdutide

GLP-1 / MetabolicResearch Use Only

Also known as: IBI362, LY3305677, GLP-1/glucagon dual agonist

Mazdutide is an investigational GLP-1 and glucagon receptor dual agonist commonly referenced in metabolic research literature. Studies describe its dual mechanism relevant to energy expenditure and appetite regulation. It has been a subject of clinical development, particularly in Asian populations.

Typical range (research)

Research literature commonly references escalating weekly amounts studied across roughly the ~3–9 mg/week range in trials

Half-life

~4–7 days (reported)

Route

Subcutaneous (research)

Common use

Metabolic and weight-management research

Common vial sizes

5 mg · 10 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

Referenced in research as a single dual-agonist molecule; combining with other incretin agents is not standard in the literature.

Reported side effects

NauseaReduced appetiteDiarrheaGastrointestinal upset

Regulatory note: Investigational; not FDA-approved. Under clinical development (regulatory approval reported in China in some sources); not approved in Canada. Research-grade material is not for human use.

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.